Catalog No.: PC-23212Not For Human Use, Lab Use Only.
ADT-1004 is an orally bioavailable prodrug of ADT-007, potent, selective pan-RAS inhibitor, selectively inhibits PDAC cells with mutant KRAS, does not impact the growth of tumors from RAS WT PDAC cells.
ADT-1004 is an orally bioavailable prodrug of ADT-007, potent, selective pan-RAS inhibitor, selectively inhibits PDAC cells with mutant KRAS, does not impact the growth of tumors from RAS WT PDAC cells.
ADT-1004 is designed to improve the water solubility and metabolic stability of ADT-007.
ADT-1004 inhibited ERK phosphorylation in PDAC tumors.
ADT-1004 blocked tumor growth and ERK phosphorylation in PDX PDAC models with KRAS G12D , KRAS G12V , KRAS G12C , or KRAS G13Q mutations.
ADT-1004 treatment increased CD4 + and CD8 + T cells in the TME consistent with exhaustion and increased MHCII + M1 macrophage and dendritic cells
ADT-1004 demonstrated superior efficacy over sotorasib and adagrasib in tumor models involving human PDAC cells resistant to these KRAS G12C inhibitors.
